It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites. We previously showed that a single dose of IPSE (Interleukin-4-inducing principle from Schistosoma eggs), a schistosome-derived host modulatory protein, can ameliorate ifosfamide-related cystitis; however, the mechanisms underlying this urotoxicity and its prevention are not fully understood. To provide insights into IPSE’s protective mechanism, we undertook transcriptional profiling of bladders from ifosfamide-treated mice, with or without pretreatment with IPSE or IPSE-NLS (a mutant of IPSE lacking nuclear localization sequence). Ifosfamide treatment upregulated a range of proinflammatory genes. The IL-1β-TNFα-IL-6 proinflammatory cascade via NFκB and STAT3 pathways was identified as the key driver of inflammation. The NRF2-mediated oxidative stress response pathway, which regulates heme homoeostasis and expression of antioxidant enzymes, was highly activated. Anti-inflammatory cascades, namely Wnt, Hedgehog and PPAR pathways, were downregulated. IPSE drove significant downregulation of major proinflammatory pathways including the IL-1β-TNFα-IL-6 pathways, interferon signaling, and reduction in oxidative stress. IPSE-NLS reduced inflammation but not oxidative stress. Taken together, we have identified signatures of acute-phase inflammation and oxidative stress in ifosfamide-injured bladder, which are reversed by pretreatment with IPSE. This work revealed several pathways that could be therapeutically targeted to prevent ifosfamide-induced hemorrhagic cystitis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9); Children’s National Medical Center, Division of Urology, Washington, USA (GRID:grid.239560.b) (ISNI:0000 0004 0482 1586)
2 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9)
3 Stanford University School of Medicine, Department of Structural Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
4 Guardant Health, Redwood City, USA (GRID:grid.168010.e)
5 King Abdulaziz City for Science & Technology (KACST), Life Science & Environment Sector, Riyadh, Saudi Arabia (GRID:grid.452562.2) (ISNI:0000 0000 8808 6435)
6 School of Pharmacy, University of Nottingham, Division of Molecular Therapeutics and Formulation, Nottingham, UK (GRID:grid.4563.4) (ISNI:0000 0004 1936 8868)
7 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9); Children’s National Medical Center, Division of Urology, Washington, USA (GRID:grid.239560.b) (ISNI:0000 0004 0482 1586); The George Washington University, Department of Urology, Washington, USA (GRID:grid.253615.6) (ISNI:0000 0004 1936 9510)